Redistributing ill-defined causes of death – a case study from the BURDEN 2020-project in Germany | Archives of Public Health | Full Text
Redistributing ill-defined causes of death – a case study from the BURDEN 2020-project in Germany | Archives of Public Health | Full Text,Redistributing ill-defined causes of death – a case study from the BURDEN 2020-project in Germany | Archives of Public Health | Full Text,First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer | Journal of Nuclear Medicine,Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression - Gynecologic Oncology,Nontuberculous mycobacteriosis (Mycobacterium chelonae): fatal outcome in a patient with severe systemic lupus erythematosus | Anais Brasileiros de Dermatologia